Table 2.
The Correlation Between miR-196a-5p Expression and Clinical Parameters in GC Patients (n=50)
| Clinical Parameters | Cases (n) | Expression Level | P value |
|---|---|---|---|
| Age (years) | 0.5247 | ||
| <60 | 14 | 1.2840 (0.8769, 1.6370) | |
| ≥60 | 36 | 0.7745 (0.3055, 1.6466) | |
| Gender | 0.1203 | ||
| Male | 40 | 1.0267 (0.5447, 1.6562) | |
| Female | 10 | 0.2490 (0.1685, 1.5564) | |
| Tumor Size (cm) | 0.0135* | ||
| <5 | 15 | 1.5146 (0.9378, 2.9162) | |
| ≥5 | 35 | 0.7281 (0.2575, 1.5735) | |
| Lymph Metastasis | 0.2819 | ||
| Absent | 3 | 2.0518 (1.4144, 3.0137) | |
| Present | 47 | 0.8263 (0.3055, 1.5635) | |
| TNM Stage | 0.0664 | ||
| III | 6 | 3.2522 (1.7643, 5.4497) | |
| IV | 44 | 0.9983 (0.3566, 1.5999) | |
| Chemotherapy Response | <0.0001* | ||
| Sensitive (CR+PR) | 25 | 0.4387 (0.2387, 0.7747) | |
| Resistant (SD+PD) | 25 | 1.5936 (1.2840, 2.8661) |
Notes: Expression levels are shown with median and quartile spacing. *p < 0.05.
Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.